Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor College of Medicine investigated whether different HER2 mutations drove different responses to therapy. They were able to identify a mutation that conferred therapeutic resistance and promoted metastatic behavior.
You may also be interested in:
Hospital readmissions for asthma are increasing among children, according to a new study, highlighting the gaps in health care for the most common chronic pediatric [...]
Psychologists have successfully trialed a new intervention which makes schoolchildren cut down on unhealthy snacking.This article was originally published on MedicalXpress.com
In 2017, the University of Wollongong (UOW) Early Start was awarded $1.25 million in funding from the Ministry of Health Prevention Research Support Program (PRSP). [...]